In recent years, the scope of research projects in HIV/AIDS has expanded at CWRU/UHC. The CWRU/UHC CFAR offers a mature environment for the study of HIV, not only in the U.S. but also on the international front with studies ranging from basic science to operational research. With the growth in the number and complexity of research projects and the increased sophistication of scientific questions asked, there has been a greater demand for expertise in biostatistics and epidemiology. To meet these demands, the CWRU/UHC CFAR instituted the Epidemiology & Biostatistics Core in 2001. The EpiBio Core is now tightly integrated into a larger Infectious Disease Epidemiology program at CWRU. By joining this program, the CFAR EpiBio Core integrates into a strong and well-established research program and can take advantage of economies of scale. The goal of the EpiBio Core is to assure high quality in the scientific process of AIDS research, whether descriptive or experimental, in the CFAR. The specific objectives of this core are: 1. To provide biostatistical and epidemiologic advice to CWRU/UHC CFAR investigators. 2. To provide study coordination through a Study and Data Coordinating Center at CWRU for both local and international studies conducted by CFAR investigators 3. To manage the collection and storage of data for CFAR clinical and epidemiologic studies 4. To provide training and faculty development opportunities in the area of Epidemiology and Biostatistics

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-15
Application #
7636809
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
15
Fiscal Year
2008
Total Cost
$222,276
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Mbonye, Uri; Wang, Benlian; Gokulrangan, Giridharan et al. (2018) Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation. J Biol Chem 293:10009-10025
Sayin, Ismail; Radtke, Andrea J; Vella, Laura A et al. (2018) Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med 215:1531-1542
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Martinez, Leonardo; Shen, Ye; Handel, Andreas et al. (2018) Effectiveness of WHO's pragmatic screening algorithm for child contacts of tuberculosis cases in resource-constrained settings: a prospective cohort study in Uganda. Lancet Respir Med 6:276-286
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Kityo, Cissy; Makamdop, Krystelle Nganou; Rothenberger, Meghan et al. (2018) Lymphoid tissue fibrosis is associated with impaired vaccine responses. J Clin Invest 128:2763-2773

Showing the most recent 10 out of 539 publications